Severe injection site reactions after subcutaneous administration of Sayana®: a retrospective, post-marketing analysis of WHO and Swiss spontaneous pharmacovigilance reports
PURPOSE Sayana® was introduced as the first depot medroxyprogesterone acetate-containing contraceptive that is administered via subcutaneous injection. Within 10 months, the Regional Pharmacovigilance Centre (RPVC) Zurich received several anonymous reports of serious local reactions afte...
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2017-05-01
|
| coleção: | Swiss Medical Weekly |
| Assuntos: | |
| Acesso em linha: | https://www.smw.ch/index.php/smw/article/view/2300 |